Drug Profile
CNC 332
Alternative Names: CNC-332; Mitocan; MitocansLatest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Cancure
- Class Antineoplastics
- Mechanism of Action Electron transport chain complex protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for preclinical development in Solid-tumours in Australia (Parenteral, Injection)
- 11 Sep 2020 Preclinical development is ongoing for Solid tumours in Australia (Cancure website, September 2020)
- 11 Sep 2020 CNC 332 is available for market-licensing as of 11 Sep 2020. www.cancure.com